Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M

Vima Therapeutics is expanding to Parkinson’s disease following early clinical results showed proof of concept for its drug in isolated dystonia, a rare neurological movement disorder. The startup says its drug could address the biology underpinning many movement disorders. The post Startup Vima Adds Parkinson’s to Movement Disorder Scope, Expanding Series A Round to $100M…

Read More

Key Facts About Medicare Drug Price Negotiation

Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year.

Read More

Michael Dalton, Ovatient

Michael Dalton is CEO of Ovatient — it’s a telehealth company built on Epic that comes out of health systems (Medical University of South Carolina and Metro Health, Cleveland, OH). It does the integration and care continuity between its medical group and health systems (a little like KeyCare which also serves health system). I asked…

Read More